ArticleJournal of clinical and experimental hepatology
Validation of Quantitative Magnetic Resonance Cholangiopancreatography Metrics in Prediction of Transplant-free Survival in Primary Sclerosing Cholangitis.
Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Qualitative magnetic resonance cholangiopancreatography (MRCP) scoring models in primary sclerosing cholangitis (PSC) are hampered by interobserver variability and evidence for quantitative MRCP has so far been limited by cohort sizes, follow-up time and lack of validation. This study aimed to validate the prognostic value of quantitative MRCP metrics in PSC in a large multicentre cohort. Method: Retrospective, cross-sectional, clinical and quantified MRCP data by MRCP+ were collected from a non-transplant and transplant centre and randomised (1:1 ratio) into a derivation and validation set. Transplant-free survival, a composite of liver transplantation and PSC-related mortality (excluding colorectal carcinoma), was the primary endpoint. Least absolute shrinkage and selection operator analysis with manual guidance was used to compose a risk classifier. Prognostic performance and risk stratification were expressed by C-statistic and hazard ratios (HRs), and were validated in the validation set. Results: A total of 224 patients were included with a median 6.8 years (Q1,Q3: 4.5, 9.8) of follow-up from MRCP onwards. Analysis identified number of strictures, proportion of 3-5 mm diameter ducts, years from diagnosis to MRCP and centre type as prognostic. The derived risk classifier showed a C-statistic of 0.72 (95% confidence interval [CI]: 0.60-0.81) and stratified effectively, with high-risk patients having threefold higher HR than low-risk patients (HR, 3.2; 95% CI: 1.6-6.4; Conclusion: This study confirms the prognostic value of quantitative MRCP (number of strictures and proportion of 3-5 mm diameter ducts) on long-term transplant-free survival in PSC and warrants further study on incorporating quantitative MRCP metrics into existing prognostic risk models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.